For the first time ever, the National Lipid Association is pleased to offer our Virtual Scientific Sessions as an on-demand product. This year's Scientific Sessions were held live and virtual December 10-12 2020. If you could not attend those dates, you can still enjoy the conference at your convenience now through March 31, 2021
If you attended the live conference, you still have access to the on-demand version through January 11, 2021. You may not claim credit for both live and on-demand versions of this activity.
Register for 2020 Virtual Annual Scientific Sessions Enduring
Included Sessions
| Please note that the agenda provided below includes the original presentation times to help you find specific content items. All sessions can be viewed at any time for the duration of your content purchase through March 31, 2021. Only accredited presentations are listed. Additional programs such as Expert Theaters and Satellite Symposia may be available to view for all or part of your purchase window; but they are NOT available for credit and their ongoing availability is NOT guaranteed. | ||
| Thursday, December 10, 2020 | ||
| 9:35AM - 9:45AM | Opening Remarks | |
| 9:45AM - 11:10AM | Session I- Cardiovascular Preventive Care in Pregnancy | |
|
9:50AM - 10:10AM |
Pregnancy and Contraception - How Should we Counsel Women with Severe Dyslipidemia? | Jennifer L. Thompson, MD |
| 10:10AM - 10:30AM | Medical Therapy during Pregnancy | Pamela B. Morris, MD, FNLA* |
| 10:30AM - 10:50AM | Medical Nutrition Therapy During High Risk Pregnancy with Severe Hypertriglyceridemia | Wahida Karmally, PhD, MS, RDN, CDE, CLS |
| 10:50AM - 11:10AM | Question & Answer Panel | |
| 11:15AM - 1:00PM | Session II- Ethical Dilemmas in Lipidology | |
|---|---|---|
| 11:20AM - 11:40AM | CVD Risk Reduction – Is Ovum Selection Ethical for FH? | James A. Trippi, MD, FNLA* |
| 11:40AM - 12:00PM | Can we Justify FH Genetic Testing Prior to the Age of Consent? | G. Kevin Donovan, MD, MA |
| 12:00PM - 12:20PM | Statins and Reproductive Health in Teens - An Accident Waiting to Happen? | Ann Liebeskind, MD, FNLA* |
| 12:20PM - 12:40PM | Does Cholesterol Screening Potentially Limit Job Opportunities? | Don P. Wilson, MD, FNLA* |
| 12:40PM - 1:00PM | Question & Answer Panel | |
| 4:00PM - 6:00PM | NLA Opening Session – Impact of Genetics on Clinical Practice- Chair Dr. Christie Ballantyne | |
| 4:05PM - 4:15PM | Case Presentation | Aliza Hussain, MD |
| 4:15PM - 4:35PM | Genetic Testing for Lipid Disorders | Zahid Ahmad, MD |
| 4:35PM - 4:55PM | Polygenic Risk Scores for CVD, Use in Practice and Potential Impact on Healthcare | Joshua W. Knowles, MD |
| 4:55PM - 5:15PM | My Patients are Ordering Direct-to-Consumer Genetic Testing- What Now? | Emily E. Brown, MGC, CGC |
| 5:15PM - 5:35PM | Genetics and Biotech therapies | Christie M. Ballantyne, MD, FNLA* |
| 5:40PM - 6:00PM | Question & Answer Panel | |
| Friday, December 11, 2020 | ||
| 8:50AM - 9:00AM | Opening Remarks | |
| 9:00AM - 10:25AM | Session III- Non-Alcoholic Fatty Liver Disease and Risk of Cardiovascular Disease: What Clinicians Need to Know | |
| 9:05AM - 9:15AM | Case Presentation of Patient with Non-Alcoholic Fatty Liver Disease | Pam R. Taub, MD |
| 9:15AM - 9:35AM | Diagnosing NAFLD and NASH in Clinical Practice and When to Refer to a Specialist | John M. Vierling, MD |
| 9:35AM - 9:50AM | Evidence Based Drug Therapy Treatment Options for NAFLD | Michael Wilkinson, MD |
| 9:50AM - 10:10AM | Lifestyle Interventions for NAFLD: Evaluation of the Evidence | Lisa B. VanWagner, MD, MSc |
| 10:10AM - 10:25AM | Question & Answer Panel | |
| 10:30AM - 10:55AM | NLA Presidents Address | |
| 10:55AM - 11:30AM | W. Virgil Brown Distinguished Award and Lectureship | John R. Guyton, MD, FNLA |
| 12:05PM - 1:30PM | Session IV- Imaging Atherosclerosis: What We Know and Gaps in Knowledge | |
| 12:10PM - 12:30PM |
Tracking Atherosclerosis with Cardiac CT |
Matthew J. Budoff, MD |
| 12:30PM - 12:50PM | Carotid Ultrasound and Brachial FMD | James H. Stein, MD |
| 12:50PM - 1:10PM | Imaging in Pediatrics- Where we Are and Where we Need to go | Elaine M. Urbina, MD, MS |
| 1:10PM - 1:30PM | Question & Answer Panel | |
| 2:40PM - 4:05PM | Session V- Let’s Talk About Sex…Hormones | |
| 2:45PM - 3:05PM | Hormone Replacement in Postmenopausal Women: Panacea or Poison? | Eliot A. Brinton, MD, FNLA |
| 3:05PM - 3:25PM | Testosterone Treatment in Men | Maamoun Salam, MD |
| 3:25PM - 3:45PM | Effects of Hormonal Therapy for Transgender Transition | Eugenia Gianos, MD, FNLA |
| 3:45PM - 4:05PM | Question & Answer Panel | |
| 4:15PM - 5:40PM | Session VI- Prevention of Atherosclerotic Cardiovascular Disease in South Asians in the US | |
| 4:20PM - 4:40PM | Epidemic of ASCVD in South Asians in the US and Strategies for Early Identification | Dinesh Kalra, MD |
| 4:40PM - 5:00PM | Diabetes and Heart Disease in South Asians in the US: Challenges and Opportunities in Management | Krishnaswami Vijayaraghavan, MD, MS, FNLA |
| 5:00PM - 5:20PM | Dyslipidemia in South Asians in the US | Nihar R. Desai, MD, MPH |
| 5:20PM - 5:40PM | Question & Answer Panel | |
| Saturday, December 12, 2020 | ||
| 10:10AM - 10:20AM | Opening Remarks | |
| 1:30PM - 3:00PM | Non-CME Special Joint Session between EAS and NLA- Dyslipidemia Treatment in Light of the New Guidelines- Chairs: Lale Tokgözoğlu, MD and Antonio M. Gotto, Jr., MD, DPhil, FNLA | |
| 1:30PM - 1:35PM | Session Introduction from Chairs | |
| Targets and Goals | ||
| 1:35PM - 1:50PM | EAS Perspectives | Alberico L. Catapano, PhD |
| 1:50PM - 2:05PM | NLA Perspectives | Carl E. Orringer, MD, FNLA |
| Therapeutic Approaches | ||
| 2:05PM - 2:50PM | EAS Recommendations & Perspectives | Lale Tokgözoğlu, MD |
| 2:50PM - 2:35PM | NLA Recommendations & Perspectives | Peter H. Jones, MD, FNLA |
| 2:35PM - 3:00PM | Question & Answer Panel | |
| 3:05PM - 4:05PM | Session IX- Scientific Statements | |
| 3:05PM - 3:10PM | Introduction of the NLA Scientific Statement on CAC | Carl E. Orringer, MD, FNLA |
| 3:10PM - 3:30PM | NLA Scientific Statement on CAC: CAC Testing and Interpretation | Matthew J. Budoff, MD |
| 3:30PM - 3:50PM | NLA Scientific Statement on CAC: CAC Guided Treatment Recommendations and other Considerations | Michael Blaha, MD |
| 3:50PM - 4:05PM | Question & Answer Panel | |
| 4:05PM - 4:25PM | Junior Faculty Research Award Presentation | Nathan Stitziel, MD, PhD |
| 4:30PM - 5:20PM | Late Breakers | |
Accreditation Information
.png)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.5 AMA PRA Category 1 Credits™ MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation Statement
The National Lipid Association designates this Internet Enduring Activity for a maximum of 12.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 12.5 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.
Pharmacist Accreditation Statement
Universal Activity Number JA0007192-0000-20-029-H04-P (Application)
This Activity has been approved for 12.5 contact hour(s) (1.250 CEUs) of the Accreditation Council for Pharmacy Education
Nursing
The maximum number of hours awarded for this CE activity is 12.6 contact hours.
Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.
Target Audience
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management.
Type of Activity
Internet Enduring Activity, Application
Educational Objectives
At the conclusion of this activity, all participants should be able to:
- Discuss strategies to improve the knowledge, skills or performance of the healthcare team.
Session I: Cardiovascular Preventive Care in Pregnancy
- Discuss potential cardiovascular risks associated with pregnancy in women with genetic dyslipidemia.
- Review strategies for managing CVD risk in pregnant women or women who plan to become pregnant.
Session II: Ethical Dilemmas in Lipidology
- Discuss ethical controversies in the practice of lipidology.
NLA Opening Session: Impact of Genetics on Clinical Practice
- Evaluate the use of genetic testing to inform risk assessment and therapeutic decisions.
- Explain the role of the genetic counselor in screening for genetic disorders.
- Review challenges in the application of genomic testing into clinical practice.
- Apply insight from human genetics to identify novel therapeutic targets.
Session III: Non-Alcoholic Fatty Liver Disease and Risk of Cardiovascular Disease: What Clinicians Need to Know
- Identify appropriate lipid management for patients with non-alcoholic fatty liver disease.
- Review appropriate diagnostic strategies in patients with non-alcoholic fatty liver disease.
- Determine therapeutic options for the treatment of non-alcoholic fatty liver disease.
W. Virgil Brown Distinguished Achievement Award and Lectureship
- Evaluate the management of patients with dyslipidemia.
Session IV: Imaging Atherosclerosis: What We Know and Gaps in Knowledge
- Review the use of imaging modalities for cardiovascular risk assessment.
Session V: Let’s Talk About Sex…Hormones
- Discuss the efficacy and safety of hormonal therapies in the management of dyslipidemia and cardiovascular risk.
Session VI: Prevention of Atherosclerotic Cardiovascular Disease in South Asians in the US
- Recognize the risk factors and interconnection of early onset diabetes and ASCVD in South Asians.
- Discuss epidemiology and risk profiles for dyslipidemia in South Asians in the United States.
Session VII: Oral Poster Presentations
- Critically appraise emerging research and its applications to daily clinical practice.
Session IX: Scientific Statements of the NLA
- Review current literature of importance to the science and practice of clinical lipidology.
NLA Junior Faculty Research Award Presentation
- Discuss the recent research impacting future management of patients with dyslipidemia.